Other

Vegenics Pty Limited

Vegenics Limited

Ludwig Institute for Cancer Research Limited

Licentia, Ltd.

Helsinki University Licensing, Ltd.

University of Pittsburgh

Helsinki University Licensing Ltd. Oy

Medimmune Limited

Eberhard-Karls-Universität Tübingen Universitätsklinikum

University of Helsinki

Ludwig Institute of Cancer Research

Vegenies Limited

Seppo Yla-Herttuala

Eberhard-Karls-Universitat Tubingen

Kari Alitalo

Vladimir Joukov

Marc Gregory Achen

Ulf Eriksson

Andrew Frederick Wilks

Steven Alan Stacker

Markku Michael Jeltsch

Katri Pajusola

Birgitta Olofsson

Marko Uutela

Arja Kaipainen

Jaana Korhonen

Taija Makinen

Carl-Henrik Heldin

Robert Ferrell

David Finegold

Stephen A Stacker

Marika Karkkainen

Karin Aase

Seppo Ylä-Herttuala

Annica Ponten

Elina Armstrong

Olga Aprelikova

Mikko O Hiltunen

Antti I Nykänen

Arne Oestman

Karl B Lemström

Ronald Herbst

Ching Ching Leow

Xuri Li

Arne Östman

Volkhard Kempf

Aude Le Roux

Marko J T Uutela

Marja-Terttu Matikainen

Simo Syrjala

Andrew F Wilks

Tanja Riess

Ingo Autenrieth

Siv Anderson

Erkki Koivunen

Hajime Kubo

Rejia Valtola

Brigitta Olofsson

Karl Lemstrom

Lolla Jussila

Olli Leppänen

Seppo Ylā-Herttuala

Tatiana Petrova

Lotta Jussila

Reija Valtola

Antti Nykanen

Erika Bergsten

Jane Connor

Ralf Pettersson

Tuomas Tammela

Seppo Ylae-Herttuala

Didier Branellec

Juha Partanen

Salla Keskitalo

Berndt Enholm

Xuri Lee

Anne Saaristo

Terhi Karpanen

Tomi Makela

Michael Jeltsch

Andrey Anisimov

Karl B LEMSTRÖM

Antti I NYKÄNEN

Li Xuri

Annica Ponton

Siv Dept Of Molecular Evolution Anderson

The disclosure is directed to methods and uses of antibodies or antigen-binding fragments thereof against Angiopoietin-2 (Ang-2). Specifically, the disclosure is direct to the use of anti-Ang2 antibodies or antigen-binding fragments thereof for treating ischemia. The methods disclosed are useful for reducing microvascular permeability, increasing microvascular perfusion, reducing inflammation in a tissue, and treating or ameliorating diseases associated with ischemia and/or reperfusion injury. The disclosed methods are also useful for protecting solid organ transplant tissue and treating or preventing chronic tissue transplant rejection.

Methods of protecting a solid organ transplant tissue with angiopoietin-2 antibodies

The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors, to prevent, inhibit, or ameliorate allograft rejection or arteriosclerosis in organisms that receive an organ transplant.

Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis

The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.

Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy

Materials and methods are provided to improve survival of lymph nodes and integration of lymph nodes into a lymphatic network, following lymph node transplantation. The treatment or prevention of lymphedema is also addressed. A method of lymph node transfer includes transferring or transplanting a lymph node or lymph node fragment in a mammalian subject; and administering a composition comprising an agent selected from the group consisting of Vascular Endothelial Growth Factor C (VEGF-C) polynucleotides, VEGF-C polypeptides, Vascular Endothelial Growth Factor D (VEGF-D) polynucleotides, and VEGF-D polypeptides to a perinodal site within 20 cm of the lymph node or lymph node fragment. In certain embodiments, the agent is present in the composition in an amount effective to promote survival of the lymph node and integration of the lymph node into a lymphatic network in the mammalian subject, at the site of transfer or transplantation.

Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery

Described herein are pharmaceutical compositions comprising a VEGF-D polypeptide.

Pharmaceutical compositions comprising a VEGF-D polypeptide

Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. Methods of inhibiting endothelial cell proliferation are also provided.

Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof

The invention also relates to a method for of enhancing the acceptance and/or healing of a skin graft in a subject comprising stimulating angiogenesis and lymphangiogenesis with an effective amount of an isolated VEGF-D polypeptide.

Method of enhancing the acceptance and/or healing of a skin graft

The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and/or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.

Use of VEGF-D gene to prevent restenosis

Disclosed herein are methods of making a VEGF-D polypeptide comprising the steps of culturing a host cell transformed or transfected with a vector comprising a nucleic acid sequence encoding the VEGF-D polypeptide operably associated with a promoter sequence such that the nucleic acid sequence encoding the VEGF-D polypeptide is expressed; and isolating the VEGF-D polypeptide from the host cell or from the growth medium in which said host cell is cultured.

Methods of making VEGF-D polypeptides

Methods of screening for neoplastic disease states

The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects.

Method of treatment for lymphedema comprising administering a polynucleotide encoding VEGF-D

The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth factors.

Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins

Growing community of inventors

Helsinki, Finland

Kari Alitalo